Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes (Tables)

v3.25.3
Income Taxes (Tables)
12 Months Ended
Sep. 30, 2025
Income Tax Disclosure [Abstract]  
Schedule of Deferred Tax Assets and Liabilities

The tax effects of the temporary differences that gave rise to deferred taxes were as follows:

 

         
    September 30,  
    2025     2024  
Deferred tax assets:                
Net operating loss carryforwards   $ 29,195,207     $ 26,754,767  
Research and development credit carryforwards     2,789,965       3,129,222  
Amortization     6,620,882       5,791,883  
Share-based compensation     39,130       19,357  
Operating lease liability     13,092       36,786  
Accrued expenses and other     24,327       26,977  
Section 163(j) disallowed interest expense     758,351       761,450  
Foreign tax credits     218,400        
Gross deferred tax assets     39,659,354       36,520,442  
Less: valuation allowance     (39,644,696 )     (36,480,967 )
Deferred tax assets     14,658       39,475  
Deferred tax liabilities:                
Property and equipment     (2,353 )     (4,782 )
Operating lease right-of-use asset     (12,305 )     (34,693 )
Net deferred tax assets   $     $  
Schedule of Effective Income Tax Rate Reconciliation

The Company recorded foreign income tax expense of $0.2 million for the year ended September 30, 2025 and no income tax expense for the year ended September 30, 2024. A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

 

    2025     2024  
    Years ended September 30,  
    2025     2024  
U.S. federal statutory rate     (21.0 )%     (21.0 )%
State taxes, net of federal benefit     (6.0 )     (5.8 )
Permanent differences     2.7       2.7  
Foreign tax rate differential           0.1  
Foreign tax credits     (1.4 )      
Foreign withholding taxes     1.4        
Research and development credit     1.8       (4.6 )
Change in valuation allowance     20.0       (8.3 )
Sale of state net operating losses and research and development credits     4.1       51.5  
Other     (0.2 )     (14.6 )
Effective income tax rate     1.4 %     %